The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine

Background. The ongoing development of a vaccine against human papillomavirus (HPV) raises important questions about the impact of various vaccination strategies. Methods. Two mathematical models are developed to explore the population-level impact of an HPV vaccine. The first model focuses on the infection process and the second on the disease process (specifically, cervical carcinoma in situ and cancer). Results. Both population characteristics (ie, sexual mixing and rates of sex partner change) and vaccine characteristics affect the steady state prevalence of HPV that would be expected if a vaccine program is implemented. Under a particular set of assumptions, we find that vaccinating both men and women against a specific HPV type would result in a 44% decrease in prevalence of that type whereas vaccinating only women would result in a 30% reduction. We also find that if a vaccine gives protection against some, but not all, high risk types of HPV, the reduction in disease may be less than the reduction in HPV because the remaining high risk HPV types may replace the disease caused by the eliminated types. Conclusions. A multivalent vaccine containing the majority of disease-causing HPV types would greatly reduce the need for colposcopy, biopsy and treatment. However, it is unlikely that Pap-screening programs would become redundant unless the vaccine is highly effective and coverage is widespread. In contrast to less common infections that are primarily restricted to core groups, targeting the vaccine towards the most sexually active individuals is less effective for a common sexually transmitted infection such as HPV.

[1]  G. Garnett,et al.  Public health paradoxes and the epidemiological impact of an HPV vaccine. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  J S Koopman,et al.  Assessing HIV vaccine effects. , 1995, American journal of epidemiology.

[3]  D. Jenkins,et al.  Withdrawing low risk women from cervical screening programmes: mathematical modelling study. , 1999, BMJ.

[4]  P. Kaye Infectious diseases of humans: Dynamics and control , 1993 .

[5]  Sally M. Blower,et al.  Imperfect vaccines and herd immunity to HIV , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[6]  D M Parkin,et al.  Estimates of the worldwide frequency of sixteen major cancers in 1980 , 1988, International journal of cancer.

[7]  V. Moreno,et al.  Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference , 2001, Journal of clinical pathology.

[8]  R. May,et al.  Directly transmitted infections diseases: control by vaccination. , 1982, Science.

[9]  N. Kiviat,et al.  Concurrent and sequential acquisition of different genital human papillomavirus types. , 2000, The Journal of infectious diseases.

[10]  D J Nokes,et al.  The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes , 1996, Epidemiology and Infection.

[11]  R. Anderson,et al.  Contact Tracing and the Estimation of Sexual Mixing Patterns: The Epidemiology of Gonococcal Infections , 1993, Sexually transmitted diseases.

[12]  G. Garnett The influence of behavioural heterogeneity on the population level effect of potential prophylactic human immunodeficiency virus type 1 vaccines , 1998 .

[13]  J. Dillner,et al.  Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. , 1999, The Journal of general virology.

[14]  D C McCrory,et al.  Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. , 2000, American journal of epidemiology.

[15]  T. Bjørge,et al.  No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11 , 1999, International journal of cancer.

[16]  M. Halloran,et al.  Cost-effectiveness of a routine varicella vaccination program for US children. , 1994, JAMA.